U.S. Markets closed
  • S&P 500

    4,136.48
    -43.28 (-1.04%)
     
  • Dow 30

    33,926.01
    -127.93 (-0.38%)
     
  • Nasdaq

    12,006.96
    -193.86 (-1.59%)
     
  • Russell 2000

    1,985.53
    -15.69 (-0.78%)
     
  • Crude Oil

    73.23
    -2.65 (-3.49%)
     
  • Gold

    1,877.70
    -53.10 (-2.75%)
     
  • Silver

    22.40
    -1.22 (-5.17%)
     
  • EUR/USD

    1.0798
    -0.0113 (-1.0366%)
     
  • 10-Yr Bond

    3.5320
    +0.1360 (+4.00%)
     
  • Vix

    18.33
    -0.40 (-2.14%)
     
  • GBP/USD

    1.2056
    -0.0173 (-1.4106%)
     
  • USD/JPY

    131.1500
    +2.5460 (+1.9797%)
     
  • BTC-USD

    23,404.44
    -183.43 (-0.78%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy

  • Mirati Therapeutics Inc (NASDAQ: MRTX) announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort of adagrasib combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in previously untreated metastatic lung cancer patients, harboring a KRASG12C mutation.

  • Early data shows that a combination treatment demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate (ORR) of 49%, with a manageable safety profile.

  • Related: Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month.

  • Wall Street analysts called the early results encouraging, Reuters reported, but shares of Mirati were down more than 8%. More trial details will be presented on Wednesday.

  • "We believe the data continue to support the regimen's differentiated positioning relative to standard of care and are far more favorable than that of Lumakras plus (immunotherapy)," a JP Morgan analyst said, referring to Amgen Inc's (NASDAQ: AMGN) drug.

  • Out of seven phase-two trial patients given the adagrasib combination, four (57%) had tumor shrinkage and a disease control rate of 100%.

  • Price Action: MRTX shares traded 9.60% lower at $83.85 during pre-market trading on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.